Isotechnika's Canadian Phase 3 psoriasis trial published
"The Lancet is one of the world's leading peer-reviewed medical journals and we are extremely honoured that this prestigious journal would acknowledge the work we are doing with voclosporin in the field of psoriasis," stated Dr. Robert Foster, Isotechnika Chairman & CEO. "To that end, we would also like to take this opportunity to thank all of the patients, investigators and study coordinators who participated in the trial. Without them we would not be able to advance voclosporin through the clinical trial process."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.